Neoadjuvant endocrine treatment of women with breast cancer

Neoadjuvant endocrine treatment of women with breast cancer

Neoadjuvant therapy has four goals in breast cancer: decrease tumor volume to operate tumors that initially were inoperable, increase the number of conservative surgeries, evaluate the chemosensitivity in vivo and analyze the management of micrometastases. Neoadjuvant treatment provides a unique set...

Full description

Bibliographic Details
Main Authors:	Julian Iturbe, Ariel Zwenger, Carlos Vallejo, Bernardo Leone, Pablo Leone
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2011-09-01
Series:	Oncology Reviews
Subjects:	Breast cancer - Neoadjuvant therapy - Hormone therapy Tamoxifen - Aromatase inhibitors
Online Access:	http://www.oncologyreviews.org/index.php/or/article/view/30

Similar Items

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review
by: Tomás Reinert, et al.
Published: (2016-12-01)

Adverse effects of adjuvant endocrine therapy
by: E. I. Kovalenko, et al.
Published: (2018-07-01)

Identifying determinants of adherence to adjuvant endocrine therapy following breast cancer: A systematic review of reviews
by: Adam Todd, et al.
Published: (2024-02-01)

Adjuvant hormone therapy in postmenopausal patients with locally advanced breast cancer: hope and reality
by: V. I. Borisov
Published: (2014-07-01)

The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review
by: Leanne Fleming, et al.
Published: (2022-08-01)

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
by: Roberta Rosso, et al.
Published: (2023-01-01)

Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South Korea
by: Jooyoung Oh, et al.
Published: (2022-09-01)

Is the extension of adjuvant hormone therapy for breast cancer justified?
by: V. F. Semiglazov, et al.
Published: (2020-07-01)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
by: Nobuaki Sato, et al.
Published: (2018-07-01)

Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trialResearch in context
by: Sylvie Giacchetti, et al.
Published: (2024-06-01)

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
by: Hao Liao, et al.
Published: (2022-05-01)

Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysisResearch in context
by: Andri Papakonstantinou, et al.
Published: (2025-03-01)

Breast ductal carcinoma in situ: a literature review of adjuvant hormonal therapy
by: Stephen Kinsey-Trotman, et al.
Published: (2016-12-01)

Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer
by: Al-Batsh T, et al.
Published: (2025-03-01)

Women’s Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions
by: Brittany Humphries, et al.
Published: (2018-06-01)

Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study
by: Luca Arecco, et al.
Published: (2024-10-01)

Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects
by: Fatima Khan, et al.
Published: (2023-02-01)

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
by: V. F. Semiglazov, et al.
Published: (2018-07-01)

Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8
by: Guy Jerusalem, et al.
Published: (2023-12-01)

CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer
by: Malin Dahlgren, et al.
Published: (2023-06-01)

The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy
by: Jing Xu, et al.
Published: (2023-07-01)

Abrogating endocrine resistance by targeting ER alpha and PI3K in breast cancer
by: Emily M Fox, et al.
Published: (2012-10-01)

Research progress and prospects of neoadjuvant endocrine therapy for breast cancer
by: QIAN Yao, LIU Feng
Published: (2022-07-01)

The effectiveness of controlled ovarian stimulation with tamoxifen for patients with estrogen‐sensitive breast cancer: A systematic review and meta‐analysis
by: Tsukasa Yoshida, et al.
Published: (2023-01-01)

Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data
by: Sung Hyouk Choi, et al.
Published: (2020-12-01)

Breast cancer anti-hormonal therapy and rheumatic diseases: linking the clinical to molecular world
by: Nadia Melillo, et al.
Published: (2020-04-01)

Prognostic Impact of Menopausal Hormone Therapy in Breast Cancer Differs According to Tumor Characteristics and Treatment
by: Christopher Godina, et al.
Published: (2020-02-01)

Evaluation of Arthralgia Induced by Aromatase Inhibitor Therapy
by: Gulabi Mese, et al.
Published: (2013-02-01)

Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trialResearch in context
by: Vivianne C.G. Tjan-Heijnen, et al.
Published: (2023-04-01)

Lipid changes during endocrine therapy in early-stage breast cancer patients: A real-world study
by: Yuechong Li, et al.
Published: (2024-01-01)

Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation
by: Maha F. Althuwaibi, et al.
Published: (2023-06-01)

Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy
by: Fumikata Hara, et al.
Published: (2010-04-01)

Primary endocrine therapy of locally advanced breast cancer patients
by: Nešković-Konstantinović Zora B.
Published: (2003-01-01)

Neoadjuvant treatment for breast cancer
by: V. F. Semiglazov, et al.
Published: (2014-07-01)

Effect of neuromuscular taping on musculoskeletal disorders secondary to the use of aromatase inhibitors in breast cancer survivors: a pragmatic randomised clinical trial
by: Inmaculada Conejo, et al.
Published: (2018-06-01)

The immune microenvironment characterisation and dynamics in hormone receptor–positive breast cancer before and after neoadjuvant endocrine therapy
by: Gizem Oner, et al.
Published: (2023-09-01)

Musculoskeletal events associated with the management of endocrine-responsive breast cancer
by: Anas Al-Janadi, et al.
Published: (2011-12-01)

Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer
by: Ida Dragvoll, et al.
Published: (2022-12-01)

Endocrine issues and premenopausal breast cancer
by: Mara Carsote, et al.
Published: (2021-12-01)

Preoperative Hormone Therapy in the Treatment of Breast Cancer: What Do We Know So Far?
by: V. V. Vorotnikov, et al.
Published: (2022-10-01)